Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 81 entries
View as:

Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT03269227 Org: User:
Start: 08/14/17 End: 12/31/23 Due: 12/31/24

PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI

Phase: N/A Priority: Normal
NCT ID: NCT02479490 Org: User:
Start: 09/22/15 End: 09/30/17 Due: 09/30/18

Experimental Study to Evaluate the Impact of 18 Fluoro-PSMA (18F-PSMA) PET / CT in the Management of Patients with Prostate Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT04775602 Org: User:
Start: 07/31/20 End: 07/11/24 Due: 07/11/25

A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT02225652 Org: User:
Start: 09/30/10 End: 07/31/14 Due: 07/31/15

"Receptor Radionuclide Therapy With 177Lu-DOTATOC

Phase: N/A Priority: Normal
NCT ID: NCT06045260 Org: User:
Start: 09/13/23 End: 01/31/27 Due: 01/31/28

Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM) Staging.

Phase: N/A Priority: Normal
NCT ID: NCT03465579 Org: User:
Start: 05/23/18 End: 09/03/24 Due: 09/03/25

Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02736500 Org: User:
Start: 09/02/15 End: 10/22/19 Due: 10/22/20

Medication Reconciliation in Oncologic Patients

Phase: N/A Priority: Normal
NCT ID: NCT04796142 Org: User:
Start: 06/12/19 End: 09/15/23 Due: 09/15/24

68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated

Phase: N/A Priority: Normal
NCT ID: NCT02920229 Org: User:
Start: 11/30/15 End: 10/09/20 Due: 10/09/21

Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression

Phase: N/A Priority: Normal
NCT ID: NCT02919462 Org: User:
Start: 03/31/16 End: 05/31/17 Due: 05/31/18

Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies

Phase: N/A Priority: Normal
NCT ID: NCT03546426 Org: User:
Start: 12/12/19 End: 09/30/28 Due: 09/30/29

Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)

Phase: N/A Priority: Normal
NCT ID: NCT05893381 Org: User:
Start: 06/27/23 End: 04/30/32 Due: 04/30/33

Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:

Phase: N/A Priority: Normal
NCT ID: NCT05867615 Org: User:
Start: 05/25/23 End: 12/31/28 Due: 12/31/29

Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study

Phase: N/A Priority: Normal
NCT ID: NCT01973322 Org: User:
Start: 10/08/13 End: 06/20/24 Due: 06/20/25

Skin Toxicity by Oncological Therapies

Phase: N/A Priority: Normal
NCT ID: NCT05109858 Org: User:
Start: 03/21/19 End: 02/28/25 Due: 02/28/26

InteGRAtive Analysis of TuMor, Microenvironment, ImmunitY and Patient Expectation for Personalized Response Prediction in Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04842916 Org: User:
Start: 09/22/20 End: 05/22/27 Due: 05/22/28

Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)

Phase: N/A Priority: Normal
NCT ID: NCT05623319 Org: User:
Start: 03/27/23 End: 07/31/27 Due: 07/31/28

Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)

Phase: N/A Priority: Normal
NCT ID: NCT04300101 Org: User:
Start: 05/14/20 End: 05/31/28 Due: 05/31/29

Italian Observational Study of Patients With Acute Myeloid Leukemia Treated With Small Molecule Inhibiting BCL-2

Phase: N/A Priority: Normal
NCT ID: NCT04070807 Org: User:
Start: 08/23/19 End: 12/31/20 Due: 12/31/21

Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03453528 Org: User:
Start: 07/04/17 End: 01/03/25 Due: 01/03/26

Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06522919 Org: User:
Start: 01/07/25 End: 09/01/26 Due: 09/01/27

Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation

Phase: N/A Priority: Normal
NCT ID: NCT02477813 Org: User:
Start: 01/31/15 End: 06/30/18 Due: 06/30/19

Implementing an Evidence-based Computerized Decision Support System Linked to Electronic Health Records to Improve Care for Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT02645357 Org: User:
Start: 11/30/15 End: 01/31/17 Due: 01/31/18

Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)

Phase: N/A Priority: Normal
NCT ID: NCT04363827 Org: User:
Start: 05/14/20 End: 09/30/21 Due: 09/30/22

Whole Body MRI in Oncology

Phase: N/A Priority: Normal
NCT ID: NCT06895291 Org: User:
Start: 10/26/23 End: 10/31/31 Due: 10/31/32